Redeye notes that Xplora Technologies delivered a record EBITDA of NOK51m, 11% above Redeye research...
Redeye state’s Safello’s Q2 2025 presented top-line headwinds with net sales of SEK130.
Administer's Q2 was slightly weaker than expected, with the y/y EBITDA improvement streak coming to ...
Aspo reports Q2 results on Aug 18. Telko and Leipurin are on a steady track to improve more after la...
Endomines delivered a strong performance in H1, despite a slight shortfall relative to our profitabi...
Marimekko’s domestic sales proved more resilient in Q2 than we expected while international growth w...
Relais' Q2 adjusted EBITA came in well in line with LSEG Data & Analytics consensus expectations.
We lower 2025E adjusted EBIT by 10% yet keep 2026E-27E adjusted EBIT largely intact (+2%), as we fin...
Återhämtningen av marginalen går fortare än väntat och omsättningen är på spåret.
- Earnings disappointment in Q2, but strong cash flow - We lower our US and Germany EBIT estimates -...
Voi, som är VNV Globals näst största innehav, kom med en mycket stark Q2-rapport.
Redeye comments on Bredband2’s Q2 report which posted marginally stronger performance across the boa...
Relais Q2 adjusted EBITA of EUR 7.6m was up 3% y/y and came 2% above LSEG Data & Analytics consensus...
Redeye retains its positive view of Transtema following a Q2 report that aligns with our expectation...
Redeye comments on Embracer’s Q1-results which were weaker than expected, owing mainly to soft perfo...
Redeye provides an update on Scandinavian ChemoTech following the Q2 2025 report.
Redeye comments on the SEK2.2m milestone bonus payment received for a game under a work-for-hire agr...
Taaleri's Q2 results came largely in line with our expectations on an underlying basis, owing to goo...
EQL Pharma redovisade ökad nettoomsättning och EBIT i det första kvartalet.
EBIT -9% vs cons, -15% vs ABGSC Order backlog +25%, organic growth +43% y-o-y We expect limited esti...